A clinical trial has shown that the immunotherapy drug pembrolizumab increased survival rates for head and neck cancer patients with intermediate risk.

Using computer drug simulations, researchers have found that doctors need to be wary of prescribing a promising treatment for all types of cancer and patients.

Many people have to take statins to lower their cholesterol levels. But statins may be able to do even more: Researchers report that these drugs inhibit a gene that promotes cancer cell metastasis.

Researchers have developed a new pH probe and imaging technique to provide researchers more information when studying diseases like cancer and Alzheimer’s.

Researchers have uncovered a new role of a chromatin-modulatory enzyme, termed EZH2, during cancer development. They then designed a new small-molecule, MS177, based on the proteolysis-targeting chimera (PROTAC) technology, that targets both EZH2 and cMyc and thus inhibits cancer growth.

Scientists say the unexpected discovery about small-cell lung cancer could lead to new treatment approaches for that cancer and other forms of cancer as well.

Researchers have uncovered how a process involved in the regeneration of tissue damaged by radiation can aid the spread of cancer.

A new study shows how certain RNA molecules control the repair of damaged DNA in cancer cells, a discovery that could eventually give rise to better cancer treatments.

Annual MRI screenings starting at ages 30 to 35 may reduce breast-cancer mortality by more than 50% among women who carry certain genetic changes in three genes, according to a comparative modeling analysis. The predictions involve pathogenic variants in ATM, CHEK2 and PALB2 genes — which collectively are as prevalent as the much-reported BRCA1/2 gene mutations.

Scientists have developed mathematical models that act as patient ’surrogates‘ for evaluating potential prostate cancer treatments.

Researchers found that some cancer cells weave a deactivating signal into a protective coat of armor, immobilizing and excluding T cells that would otherwise kill them. This immune deactivation pathway offers a promising new therapeutic approach for pancreatic, breast, and colorectal cancers.

Researchers surveyed and compared early- and late-stage breast and colorectal cancer diagnoses in patients in pre-pandemic 2019 and in 2020, the first full year of the COVID-19 pandemic, discovering fewer of the former and more of the latter as patients delayed care.

A new study shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to ixabepilone (IXA) alone.

A study is validating the use of genomic sequencing to predict the likelihood that patients with gastric cancer will derive benefit from chemotherapy or from immunotherapy.

A new study found in a living embryo that the back ends of moving cell groups push the group forward, with implications for how organs form and cancer spreads.

Nanomaterials have revolutionized the world of cancer therapy, and plant-derived nanoparticles have the added advantage of being cost-effective and easy to mass produce. Researchers have recently developed novel corn-derived bionanoparticles for targeting cancer cells directly, via an immune mechanism. The results are encouraging, and the technique has demonstrated efficacy in treating tumor-bearing laboratory mice. Moreover, no serious adverse effects have been reported in mice so far.

Bile duct cancer, also known as cholangiocarcinoma (CCA), is a rare cancer often diagnosed only at an advanced stage. A comprehensive analysis of diagnostic, prognostic, and therapeutic aspects of over 2,200 patients in Europe now provides a valuable knowledge base for raising awareness and managing CCA to improve outcomes.

Researchers discovered how ovarian cancer hides from the body’s immune system. The findings will help develop novel precision therapies for ovarian cancer, a common and aggressive cancer type.

Researchers have created a functional catalog of proteins that activate gene expression, with implications for tailored therapy for cancer and other diseases that occur when wrong genes are switched on.

Researchers have identified a previously unrecognized key player in cancer evolution: clusters of mutations occurring at certain regions of the genome. These mutation clusters contribute to the progression of about 10% of human cancers and can be used to predict patient survival.

Researchers have shown how probiotic bacteria in the gut could undermine immunity in pancreatic cancer, pointing toward more personalized cancer treatments.

When tumors spread, cancer cells migrate to other parts of the body through the blood or lymphatic vessels. Scientists have now found a new protein that prevents cancer cells from doing so by making them stick more tightly to their surroundings. Their findings could in the future help doctors determine the aggressiveness of a tumor and fine-tune the therapy.

In many mammals including humans, the placenta invades the wall of the uterus during pregnancy in the same way that cancer cells invade surrounding tissues. Using genomic sequences and gene expression information, researchers were able to predict specific signaling proteins that drive the expression of genes that decrease the susceptibility of invasion in human cells. Using a custom fabricated bio chip, the researchers confirmed that these predicted proteins did in fact decrease the invasion of both cancer and placental cells.

Researchers have developed a new protocol for monitoring acute lymphoblastic leukemia (ALL), the most common cancer in children, to inform more effective treatment strategies and detect disease recurrence. The personalized mediator probe PCR (MP PCR) uses multiple genomic cancer cell markers in a single assay and is simpler than current techniques. It improves monitoring clonal tumor evolution to detect a relapse sooner and avoid false negative results.

Mice are typically used as models in advanced prostate cancer research, but the profound differences between them and humans has long bedeviled the translation of findings from the animal to success in people. Dogs however are the only other animal that suffers from a significant incidence of prostate cancer, and researchers are finding them much more enlightening subjects in identification of drugs that show promise for human patients.